New hope for advanced colon cancer: combo therapy enters trial
NCT ID NCT07502014
First seen Apr 09, 2026 · Last updated May 01, 2026 · Updated 6 times
Summary
This study tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) and targeted radiation to a standard targeted therapy (fruquintinib) can help people with metastatic colorectal cancer that has not responded to at least two prior treatments. About 60 adults aged 18-75 with limited spread (up to 5 tumors) will be randomly assigned to receive the combination or fruquintinib alone. The main goal is to see if the combination delays cancer growth or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.